Autoimmune Atypical Parkinsonism: A 10 year follow up of the original cohort.

IF 2.7 4区医学 Q2 CLINICAL NEUROLOGY

Neurological Sciences Pub Date : 2025-04-01 Epub Date: 2025-01-23 DOI:10.1007/s10072-025-07995-1

Sreelakshmi Sunil Kumar, Sudheeran Kannoth, Vivek Nambiar, Siby Gopinath, Anandkumar Anandakuttan, Saraf Udit Umesh, Gopikrishnan Unnikrishnan, Meena Thevarkalam, Annamma Mathai, Uday Kumar Rangaswamy, Abish Sudhakar

{"title":"Autoimmune Atypical Parkinsonism: A 10 year follow up of the original cohort.","authors":"Sreelakshmi Sunil Kumar, Sudheeran Kannoth, Vivek Nambiar, Siby Gopinath, Anandkumar Anandakuttan, Saraf Udit Umesh, Gopikrishnan Unnikrishnan, Meena Thevarkalam, Annamma Mathai, Uday Kumar Rangaswamy, Abish Sudhakar","doi":"10.1007/s10072-025-07995-1","DOIUrl":null,"url":null,"abstract":"Background: In this research, we extend our initial study in 2016 of a distinct cohort diagnosed with autoimmune atypical parkinsonism, assessing the long-term effects of immunotherapy over a decade.Objective: To study the long-term effects of immunotherapy in patients with autoimmune atypical parkinsonism over 10 years.Design: Retrospective Observational Study Design STUDY SETTING: The study was carried out at the Department of Neurology at Amrita Institute of Medical Sciences, Kochi, Kerala. The cohort described in our previous study were followed up using data from EMR or by telecommunication.Measurements: The authors utilized 9q-mRS scores to assess the disability scores and Kaplan-Meier life tables, using months as the time scale, to estimate the survival of patients with autoimmune atypical parkinsonism who underwent immunotherapy.Results: Six out of 10 patients expired, but they experienced a good improvement in their 9q-mRS scores during their treatment. Out of the 4 surviving patients, 3 exhibited outstanding responses to immunotherapy while one maintained stable 9q-mRS over an extended period. Kaplan-Meier survival analysis revealed a mean survival time of 74.7 months and a median of 68 months, with 40% of cases censored.Conclusions: Immunotherapy significantly improved the disability scores in patients with autoimmune atypical parkinsonism.","PeriodicalId":19191,"journal":{"name":"Neurological Sciences","volume":" ","pages":"1883-1890"},"PeriodicalIF":2.7000,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurological Sciences","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10072-025-07995-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: In this research, we extend our initial study in 2016 of a distinct cohort diagnosed with autoimmune atypical parkinsonism, assessing the long-term effects of immunotherapy over a decade.

Objective: To study the long-term effects of immunotherapy in patients with autoimmune atypical parkinsonism over 10 years.

Design: Retrospective Observational Study Design STUDY SETTING: The study was carried out at the Department of Neurology at Amrita Institute of Medical Sciences, Kochi, Kerala. The cohort described in our previous study were followed up using data from EMR or by telecommunication.

Measurements: The authors utilized 9q-mRS scores to assess the disability scores and Kaplan-Meier life tables, using months as the time scale, to estimate the survival of patients with autoimmune atypical parkinsonism who underwent immunotherapy.

Results: Six out of 10 patients expired, but they experienced a good improvement in their 9q-mRS scores during their treatment. Out of the 4 surviving patients, 3 exhibited outstanding responses to immunotherapy while one maintained stable 9q-mRS over an extended period. Kaplan-Meier survival analysis revealed a mean survival time of 74.7 months and a median of 68 months, with 40% of cases censored.

Conclusions: Immunotherapy significantly improved the disability scores in patients with autoimmune atypical parkinsonism.

查看原文本刊更多论文

自身免疫性非典型帕金森病：原始队列的10年随访

背景：在这项研究中，我们扩展了我们在2016年对一个诊断为自身免疫性非典型帕金森病的独特队列的初步研究，评估了免疫治疗十年来的长期效果。目的：探讨免疫治疗对10年以上自身免疫性非典型帕金森病患者的远期疗效。设计：回顾性观察性研究设计研究环境：该研究在喀拉拉邦高知Amrita医学科学研究所神经内科进行。在我们之前的研究中描述的队列使用电子病历或电信数据进行随访。测量方法：作者使用9q-mRS评分评估残疾评分和Kaplan-Meier生命表，以月为时间尺度，估计自身免疫性非典型帕金森患者接受免疫治疗的生存率。结果：10例患者中有6例死亡，但在治疗期间他们的9q-mRS评分有了很好的改善。在4名存活的患者中，3名对免疫治疗表现出出色的反应，而1名在较长时间内保持稳定的9q-mRS。Kaplan-Meier生存分析显示，平均生存时间为74.7个月，中位生存时间为68个月，40%的病例被切除。结论：免疫治疗可显著改善自身免疫性非典型帕金森病患者的失能评分。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neurological Sciences 医学-临床神经学

CiteScore

6.10

自引率

3.00%

发文量

743

审稿时长

4 months

期刊介绍： Neurological Sciences is intended to provide a medium for the communication of results and ideas in the field of neuroscience. The journal welcomes contributions in both the basic and clinical aspects of the neurosciences. The official language of the journal is English. Reports are published in the form of original articles, short communications, editorials, reviews and letters to the editor. Original articles present the results of experimental or clinical studies in the neurosciences, while short communications are succinct reports permitting the rapid publication of novel results. Original contributions may be submitted for the special sections History of Neurology, Health Care and Neurological Digressions - a forum for cultural topics related to the neurosciences. The journal also publishes correspondence book reviews, meeting reports and announcements.